Suzhou Ribo Life Science Co., Ltd. (Stock Code: 06938, RIBOLIFE-B) disclosed monthly return information for the period ended February 28, 2026. The total issued H shares rose from 165.81 million to 170.55 million following the full exercise of an over-allotment option on February 10, 2026, contributing an additional 4.74 million shares.

The authorized share capital increased accordingly from RMB 165.81 million to RMB 170.55 million. The issuer confirmed that public float requirements were met at a minimum prescribed threshold of 15.61%.

The report also noted 2.11 million outstanding share options with an exercise price of RMB 3.70 each. No options were exercised during the month, and the earliest vesting date begins in January 2028.